Is Kezar Life Sciences Inc (KZR) overvalued? · $53.9M cap
Kezar Life Sciences Inc (KZR) is a biotechnology company listed on NASDAQ.
This page asks whether Kezar Life Sciences Inc (KZR) looks expensive on cached numbers — not a short thesis.
Latest reported KZR revenue for 2024-12-31 was $0. Net income was -$83.7M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. KZR currently screens at market cap $53.9M.
KZR currently screens at market cap $53.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next KZR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the KZR stock page for the full model, not this heading.
Not investment advice.